These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
359 related items for PubMed ID: 11908197
1. Outpatient allografting in hematologic malignancies and nonmalignant disorders--applying lessons learned in the canine model to humans. Maris M, Storb R. Cancer Treat Res; 2002; 110():149-75. PubMed ID: 11908197 [Abstract] [Full Text] [Related]
2. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H. Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713 [Abstract] [Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL. Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [Abstract] [Full Text] [Related]
4. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Mapara MY, Pelot M, Zhao G, Swenson K, Pearson D, Sykes M. Biol Blood Marrow Transplant; 2001 May; 7(12):646-55. PubMed ID: 11787527 [Abstract] [Full Text] [Related]
5. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, Zhao X, Rodgers GP, Powell JD, Tisdale JF. JAMA; 2014 Jul 02; 312(1):48-56. PubMed ID: 25058217 [Abstract] [Full Text] [Related]
13. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease. Petersen SL, Madsen HO, Ryder LP, Svejgaard A, Masmas TN, Dickmeiss E, Heilmann C, Vindeløv LL. Biol Blood Marrow Transplant; 2004 May 01; 10(5):337-46. PubMed ID: 15111933 [Abstract] [Full Text] [Related]
14. Non-myeloablative hematopoietic stem cell transplantation. Maris M, Sandmaier BM, Maloney DG, McSweeney PA, Woolfrey A, Chauncey T, Shizuru J, Niederwieser D, Blume KG, Forman S, Storb R. Transfus Clin Biol; 2001 Jun 01; 8(3):231-4. PubMed ID: 11499966 [Abstract] [Full Text] [Related]
15. Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century. Maris M, Woolfrey A, McSweeney PA, Sandmaier BM, Nash RA, Georges G, Maloney DG, Molina A, Chauncey T, Yu C, Zaucha JM, Blume KG, Shizuru J, Niederwieser D, Storb R. Front Biosci; 2001 Aug 01; 6():G13-6. PubMed ID: 11487474 [Abstract] [Full Text] [Related]